<DOC>
	<DOCNO>NCT01802749</DOCNO>
	<brief_summary>Bevacizumab find prolong progression free survival first line , recently , second line treatment platinum sensitive ovarian cancer patient receive prior treatment bevacizumab . Recently report data suggest patient colon cancer receive bevacizumab one line therapy ( beyond progression ) good result . In ovarian cancer , role bevacizumab administer first second-line therapy need define . This study aim evaluate whether administer bevacizumab combination chemotherapy second-line therapy patient recurrent ovarian cancer receive first-line bevacizumab effective chemotherapy alone .</brief_summary>
	<brief_title>Bevacizumab Beyond Progression Platinum Sensitive Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patient ≥18 year age . Patients histologically confirm epithelial ovarian fallopian tube carcinoma primary peritoneal carcinoma , include mixed Mullerian Tumours Recurrence progression least 6 month last chemotherapy cycle first line carboplatin + paclitaxel chemotherapy include bevacizumab ( recurrence progression might occur either bevacizumab maintenance ) Patients include RECIST progression , either measurable nonmeasurable disease ECOG ( Eastern Cooperative Oncology Group Performance ) Status 02 . Life expectancy least 12 week . Signed informed consent obtain prior initiation studyspecific procedure treatment confirmation patient 's awareness willingness comply study requirement include blood sample molecular analysis . Availability tumour sample molecular analysis primary surgery ( mandatory ) secondary surgery ( available ) Cancer related Ovarian tumour low malignant potential ( i.e . borderline tumour ) History evidence synchronous primary endometrial carcinoma , unless follow criterion relate endometrial carcinoma meet : stage ≤Ia superficial myometrial invasion lymphovascular invasion poorly differentiate ( grade 3 papillary serous clear cell carcinoma ) . Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . Prior current plan treatment : More one previous chemotherapy line Previous therapy antiangiogenetic agent different bevacizumab . Any prior radiotherapy pelvis abdomen . Surgery ( include open biopsy ) within 4 week prior first bevacizumab dose.Current recent ( within 10 day prior first study drug dose ) use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose ( except line patency , case international normalize ratio [ INR ] must maintain 1.5 ) . Post operative prophylaxis low molecular weight heparin sc allow . Current recent ( within 30 day first study dose ) treatment investigational drug . Laboratory : Inadequate bone marrow function : ANC ( absolute neutrophil count ) : &lt; 1500/mm3 , platelet count &lt; 100,000/mm3 Haemoglobin &lt; 9 g/dl . Patients may transfuse maintain haemoglobin value ≥9 g/dl . Inadequate coagulation parameter : activate partial thromboplastin time ( APTT ) &gt; 1.5 x upper limit normal ( ULN ) INR ( international normalize ratio ) &gt; 1.5 Inadequate liver function , define : serum ( total ) bilirubin &gt; 1.5 x ULN institution AST/SGOT ALT/SGPT &gt; 2.5 x ULN . Inadequate renal function , define : serum creatinine &gt; 2.0 mg/dl &gt; 177 micromol/l urine dipstick proteinuria &gt; 2+ . Patients ≥ 1+ proteinuria baseline dipstick analysis undergo 24hour urine collection must demonstrate ≤1g protein 24hour urine collection . Prior concomitant condition procedure : History evidence brain metastasis spinal cord compression . Pregnant lactating female . History evidence thrombotic haemorrhagic disorder ; include cerebrovascular accident ( CVA ) / stroke transient ischemic attack ( TIA ) subarachnoid haemorrhage within ≤6 month prior first study treatment ) . Uncontrolled hypertension ( sustain systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg despite antihypertensive therapy ) clinically significant ( i.e . active ) cardiovascular disease , include : myocardial infarction unstable angina within ≤6 month prior first study treatment New York Heart Association ( NYHA ) grade II great congestive heart failure ( CHF ) serious cardiac arrhythmia require medication ( exception atrial fibrillation paroxysmal supraventricular tachycardia ) peripheral vascular disease ≥grade 3 ( i.e . symptomatic interfering activity daily live require repair revision ) . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess , sign impend bowel obstruction within 6 month prior first study treatment . Nonhealing wound , ulcer bone fracture . Patients granulate incision heal secondary intention evidence facial dehiscence infection eligible require three weekly wound examination . Evidence medical condition ( psychiatric illness , peptic ulcer , etc . ) , physical examination laboratory finding may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>second line</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>first line bevacizumab</keyword>
	<keyword>biologic factor</keyword>
	<keyword>clinical factor</keyword>
</DOC>